CRISPR-Based Gene Editing Market - Databook 2025 to 2034

The global CRISPR-based gene editing market size was evaluated at USD 4.04 billion in 2024 and is expected to grow around USD 13.39 billion by 2034, registering a CAGR of 12.73% from 2025 to 2034.

Highlights of the CRISPR-Based Gene Editing Market

• By product, the kits and reagents segment holds a dominant presence in the market in 2024.
• By product, the services segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By gene editing modality, the ex-vivo editing segment holds a dominant presence in the market in 2024.
• By gene editing modality, the in-vivo editing segment is anticipated to grow at the fastest rate in the CRISPR-based gene editing market during the forecast period.
• By technology, the CRISPR/Cas9 technology segment holds a dominant presence in the market in 2024.
• By technology, the CRISPR/Cas12 technology segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By application, the therapeutic applications segment holds a dominant presence in the market in 2024.
• By application, the agriculture and livestock segment is anticipated to grow at the fastest rate in the market during the forecast period.
• By end-user, the biotechnology and pharmaceutical companies segment dominated the market in 2024.
• By end-user, the agricultural and livestock industry segment is anticipated to grow at the fastest rate in the market during the forecast period.
• North America dominated the global CRISPR-based gene editing market in 2024.
• Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.

Industry Valuation and Growth Rate Projection

The CRISPR-based gene editing market involves the synthesis and use of technologies programmed to permit precise and efficient modification of DNA, which are becoming progressively integral to a variety of fields, including agriculture, therapeutic development, and biomedical research, due to their specificity, versatility, and transformative potential over multiple sectors. Growing knowledge among clinicians, researchers, and regulators about the therapeutic potency of CRISPR is accelerating its acceptance across various sectors. CRISPR and other similar gene editing technologies are being studied for their potential in curing conditions such as AIDS and HIV infections by specifically targeting and removing the virus DNA from the infected cells.

Despite the high level of interest in CRISPR and other gene editing technologies, there are several safety concerns related to the development of gene editing. Gene editing technologies as a whole are raising ethical issues due to the potential for abuse with the development of CRISPR babies, which is seen by many as selective breeding. Despite these obstacles to market growth, gene-editing knowledge is fostering more rapid clinical trials, earlier-stage research investments, and stronger support for regulatory pathways that permit faster, yet safer, market entry for gene-editing therapies.

CRISPR-Based Gene Editing Market: Stats and Figures

• In May 2023, Agilent Technologies Inc. disclosed that the firm intends to appeal the U.S. Patent and Trademarks Office (USPTO) Patent Trial and Appeal Board’s (PTAB) Final Written Decision in collaboration with the Inter Partes review (IPR). The PTAB recently reversed the USPTO’s original decision granting claims directed towards chemically modified synthetic CRISPR guide RNA.
• Horizon Discovery Group plc disclosed the addition of single-cell RNAseq-associated pooled CRISPR screening to its CRISPR screening services portfolio. The platform provides high-quality screening information and biological insight to target critical gaps in target identification and validation.

Industry Leader Announcements

• Ruby Tsai, Ph.D., CEO at Applied StemCell.

“Securing a DMF for our ActiCells GMP hiPSC line, along with introducing our ActiCells GMP TARGATT™ hiPSC Knock-in Kit, represents a major advancement for the cell therapy industry,” said Ruby Tsai, Ph.D., CEO at Applied StemCell. “By providing a fully characterized, regulatory-ready iPSC platform, we empower researchers to accelerate development while reducing manufacturing and regulatory hurdles.”

• ToolGen's CEO Jong Sang Ryu

ToolGen's CEO, Jong Sang Ryu, commented, "Vertex's CASGEVY was born from ToolGen's proprietary CRISPR RNP technology. As the company behind the world's first CRISPR Cas9-based gene therapy, we believe Vertex should fairly recognize ToolGen's contribution through appropriate licensing for the use of our CRISPR Cas9 and CRISPR RNP technologies in developing this innovative treatment."

How AI Has Benefitted the CRISPR-Based Gene Editing Market

Artificial intelligence (AI) transformed the field of gene therapy by permitting more precise, efficient, and customized treatments. AI tools, mainly deep learning (DL) and machine learning (ML) algorithms, are being leveraged to determine large genomic datasets, detect potential gene targets, and forecast the results of genetic modifications. These AI-driven approaches can improve gene editing techniques such as CRISPR-Cas9 by forecasting off-target effects and enhancing editing accuracy. CRISPR technology permits precise and efficient manipulation of the genome, and its application in cancer research has the potency to target specific genetic mutations that boost the expansion and spread of tumors.

Geographical Insights

The CRISPR-based gene editing market is experiencing significant growth, with North America maintaining its position as the dominant region while Europe emerges as the rapidly growing market. The Asia Pacific region is projected to be the fastest-growing in the CRISPR-based gene editing market during the forecast period.

North America

North America dominated the global CRISPR-based gene editing market in 2024. North America, mainly the US, boasts a well-known network of contributing academic institutions and research organizations such as the Broad Institute and MIT, boosting advancements in CRISPR science. Government agencies such as the National Institutes of Health (NIH) offer substantial funding for CRISPR research, encouraging innovation and accelerating breakthroughs.

Europe

Europe is experiencing rapid growth in the CRISPR-based gene editing market during the forecast period. The European Commission's initiatives, such as the European Green Deal, open possibilities for CRISPR-derived solutions, mainly in agriculture. CRISPR technology is being surveyed for treating a broad range of diseases, including cancer, genetic disorders, and rare diseases.

Asia Pacific

Asia Pacific is projected to be the fastest-growing CRISPR-based gene editing market during the forecast period. Increased disposable incomes in countries such as China and India are permitting greater access to healthcare and driving the acceptance of advanced gene editing technologies. Significant government investments in R&D are supporting indigenous abilities in gene editing technologies within the region.

Recent Developments

• In May 2025, Aldevron collaborates with Integrated DNA Technologies (IDT) to disclose the successful producers of the world’s first customized CRISPR gene editing drug products to treat an infant with urea cycle disorder (UCD).
• In April 2025, researchers from Colossal Biosciences announced the creation of three wolf pups that resemble dire wolves using CRISPR technology on ancient DNA. Dire wolves, which are related to grey wolves, have been extinct for over 10,000 years.

Competitive Landscape

The CRISPR-based gene editing market is undergoing rapid growth, driven by technological developments, increasing incidence of genetic disorders, and growing investments in research and development.

• Company Name: CRISPR Therapeutics AG
• Year of Incorporation: 2013
• Headquarters: Zug, Switzerland

CRISPR Therapeutics AG is a gene editing company. The company's products are mainly used in the healthcare industry, primarily in the treatment and prevention of both common and rare diseases.

• Company Name: Thermo Fisher Scientific, Inc.
• Year of Incorporation: 1956
• Headquarters: Waltham, Massachusetts, United States

Thermo Fisher Scientific Inc. (Thermo Fisher) provides analytical instruments, specialty diagnostics, life sciences solutions, laboratory, pharmaceutical, and biotechnology services. It markets products via a direct sales force, electronic commerce, customer-service professionals, and third-party distributors.

• Company Name: Agilent Technologies, Inc.
• Year of Incorporation: 1999
• Headquarters: Santa Clara, California, United States

Agilent Technologies targets competition from numerous companies in the market for laboratory solutions and analytical instrumentation. These companies provide similar products and services, including software and instruments, targeting the same end markets such as research, pharmaceuticals, and diagnostics.